Lupin Plans Major Upgrade At Plant To Produce 80-Plus Bulk Drug Types
This article was originally published in PharmAsia News
Executive Summary
Lupin said it plans to spend $43.6 million to expand one of its manufacturing plants to produce bulk forms of drugs for treating cardiac, infections, neurological problems and tuberculosis.